# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $56 pric...
JP Morgan analyst Eric Joseph maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and lowers the price target fro...
Wedbush analyst Robert Driscoll reiterates Revolution Medicines (NASDAQ:RVMD) with a Outperform and maintains $59 price target.
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and lowers the price target from $62 to $61.
Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate o...
Barclays analyst Peter Lawson maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price target fro...
Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target fro...
B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target...